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Abstract
The transcription factor NF-kB regulates numerous inflammatory diseases, and proteins involved in the NF-kB-activating
signaling pathway are important therapeutic targets. In human umbilical vein endothelial cells (HUVECs), TNF-a-induced
IkBa degradation and p65/RelA phosphorylation regulate NF-kB activation. These are mediated by IKKs (IkB kinases) viz.
IKKa, b and c which receive activating signals from upstream kinases such as Akt. Akt is known to be positively regulated by
PI-3K (phosphoinositide-3-kinase) and differentially regulated via Protein kinase A (PKA) in various cell types. However, the
involvement of PKA/Akt cross talk in regulating NF-kB in HUVECs has not been explored yet. Here, we examined the
involvement of PKA/Akt cross-talk in HUVECs using a novel compound, 2-methyl-pyran-4-one-3-O-b-D-29,39,49,69-tetra-O-
acetyl glucopyranoside (MPTAG). We observed that MPTAG does not directly inhibit IKK-b but prevents TNF-a-induced
activation of IKK-b by blocking its association with Akt and thereby inhibits NF-kB activation. Interestingly, our results also
revealed that inhibitory effect of MPTAG on Akt and NF-kB activation was unaffected by wortmannin, and was completely
abolished by H-89 treatment in these cells. Thus, MPTAG-mediated inhibition of TNF-a-induced Akt activation was
independent of PI-3K and dependent on PKA. Most importantly, MPTAG restores the otherwise repressed activity of PKA
and inhibits the TNF-a-induced Akt phosphorylation at both Thr308 and Ser473 residues. Thus, we demonstrate for the first
time the involvement of PKA/Akt cross talk in NF-kB activation in HUVECs. Also, MPTAG could be useful as a lead molecule
for developing potent therapeutic molecules for diseases where NF-kB activation plays a key role.
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Introduction
Nuclear transcription factor-kB (NF-kB) plays a central role in
inflammation and apoptosis through diverse signaling cascades.
Up-regulation of cell adhesion molecules by NF-kB on endothelial
cells is a critical step which alters the adhesive property of
vasculature and causes uncontrolled infiltration of leukocytes into
the inflamed tissue. Pharmacological inhibitors of NF-kB pathway
in endothelial cells have potential therapeutic value in treating
inflammatory diseases and cancers [1], [2]. NF-kB has been
detected in most cell types and consists of a p50/p65 heterodimer,
which is retained in the cytoplasm by the masking of nuclear
localization sequence by IkBa, the inhibitor of NF-kB [3].
Induction of human umbilical vein endothelial cells (HUVECs)
with proinflammatory stimuli such as TNF-a, IL-1b and bacterial
lipopolysaccharide (LPS) leads to IkBa phosphorylation, ubiqui-
tination, and subsequent degradation resulting in the release of
p50/p65 heterodimer [4]. The heterodimers of NF-kB migrate
into the nucleus and activate the expression of numerous target
genes that are important for inflammatory and immune responses
as well as other functions, such as the regulation of apoptosis [5]
and cell proliferation [6]. The inducible phosphorylation of IkBa
is mediated by IkB kinases (IKKs) [7]. IKKs comprises of three
subunits: IKKa/IKK1 and IKKb/IKK2, that are catalytic [8]
while the third, called IKKc or NF-kB essential modulator
(NEMO), is regulatory [9]. In human umbilical vein endothelial
cells (HUVECs), IKKs are themselves direct downstream targets
for various IKK-activating kinases such as Akt and TAK1 [10–
12]. In addition, MAP kinases, such as p38 and ERK are activated
upon TNF-a stimulation and are known to be associated with NF-
kB activation in various cell types including HUVECs [13].
Akt is activated by TNF-a through the phosphoinositide-3-
kinase (PI-3K) pathway in various cells including HUVECs. In
addition to its anti-apoptotic functions, Akt can stimulate signaling
pathways that upregulate the activity of the transcription factor
NF-kB. Wortmannin (a specific PI-3K inhibitor) or dominant-
negative PI-3K or kinase-dead Akt inhibits the TNF-a-mediated
NF-kB activation in these and other cells [14–19]. Moreover, Akt
is known to be differentially regulated via Protein kinase A (PKA)
in various cell types [20–24]. This PKA/Akt axis is poorly
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explored in NF-kB activation, compared to the classical PI-3K/
Akt pathway, and offers opportunity for drug discovery.
The present report attempts to address the yet unexplored
mechanism of PKA/Akt-dependent phosphorylation and activa-
tion of NF-kB in HUVECs. Numerous compounds, synthetic and
plant-derived, have been demonstrated to inhibit NF-kB activa-
tion either through direct PI3K inhibition or specific IKK
inhibition or proteasome pathway blockade [25–27]. However,
small molecules that inhibit NF-kB activation through modulation
of the PKA/Akt axis in TNF-a-stimulated HUVECs have not
been studied previously. Earlier, we identified 2-methyl-pyran-4-
one-3-O-b-D-glucopyranoside (MPG; Figure 1A), a novel com-
pound isolated from the leaves of Punica granatum, which inhibited
the TNF-a-induced cell adhesion molecules expression [28].
In this paper, using a novel derivative of MPG, 2-methyl-pyran-
4-one-3-O-b-D-29,39,49,69-tetra-O-acetyl glucopyranoside
(MPTAG; Figure 1B), we demonstrate for the first time that
MPTAG could inhibit the activation of NF-kB through a PI3K-
independent but PKA/Akt-dependent pathway in TNF-a-stimu-
lated HUVECs. This represents a novel mechanism of NF-kB
regulation and its implication in developing novel anti-inflamma-
tory agents is discussed.
Results
Synthesis of derivatives of MPG
Earlier, we demonstrated that MPG (Figure 1A) inhibited the
TNF-a-induced cell adhesion molecules (ICAM-1, VCAM-1 and
E-selectin) expression and adhesion of neutrophils to the
endothelium monolayer in a dose-dependent manner [28].
Encouraged with these results, we synthesized derivatives of
MPG in sufficient amounts in the laboratory (Figure S1 and Table
S1). The derivatives were tested for their solubility, cytotoxicity
and ability to inhibit the TNF-a-induced expression of ICAM-1
(intercellular cell adhesion molecule-1), VCAM-1 (vascular cell
adhesion molecule-1) and E-selectin as well as neutrophil adhesion
on human endothelial cells. The results revealed that 2-methyl-
pyran-4-one-3-O-b-D-29,39,49,69-tetra-O-acetyl glucopyranoside
(MPTAG; Figure 1B) was the most active derivative (Table S2).
We also found that it was completely water soluble and less
cytotoxic as compared to parent compound, MPG and the other
two derivatives (Tables S2 and S3). Thus, MPTAG was taken up
for further experiments to unravel its molecular mechanism of
action in HUVECs.
MPTAG inhibits TNF-a-induced NF-kB activation in
endothelial cells
Further experiments revealed that MPTAG exhibited maxi-
mum inhibition of ICAM-1, VCAM-1 and E-selectin, when added
2–4 h prior to TNF-a stimulation to human endothelial cells (data
not shown). As the promoter regions of the genes encoding cell
adhesion molecules (CAMs) contain binding site(s) for NF-kB, we
measured the transcript levels of these genes by RT-PCR
(Figure 2A). The results showed that in uninduced cells treated
with or without MPTAG, the levels of ICAM-1, VCAM-1 and E-
selectin mRNAs were very low. In contrast, upon stimulation of
cells with TNF-a, there was an upregulation in ICAM-1, VCAM-
1 and E-selectin mRNA levels. However, pretreatment of
endothelial cells with MPTAG significantly reduced the induced
mRNA levels of ICAM-1, VCAM-1 and E-selectin (Figure 2A).
Since NF-kB is a key transcription factor involved in the
expression of CAMs in endothelial cells, we determined its
activation in MPTAG-pretreated cells by EMSA (Figure 2B).
There was a low level of NF-kB activation in unstimulated cells in
absence and presence of MPTAG (lanes 1 and 7). Upon
stimulation with TNF-a, there was an increased NF-kB DNA-
binding activity as expected (lane 2). However, MPTAG
pretreatment caused a substantial reduction in this activity in a
dose-dependent manner (lanes 3–6). MPTAG pretreatment
resulted in almost complete inhibition of NF-kB DNA-binding
activity at a concentration of 400 mM (lane 3). The specificity of
the NF-kB DNA complex was confirmed by incubation of the
nuclear extract proteins with an excess of unlabeled NF-kB
oligonucleotide that inhibited the complex formation (lane 9)
whereas competition with an excess of an irrelevant oligonucle-
otide, Oct-1, did not inhibit the complex (lane 8). The specificity
was further confirmed by NF-kB supershift assay (Figure 2C). The
nuclear extracts prepared from unstimulated (lane 2) and TNF-a-
stimulated cells (lanes 3–9) were incubated with antibodies against
the p65 subunit (lane 4) or p50 (lane 5) of NF-kB. The antibodies
shifted the p65 and p50 bands to higher molecular mass (lanes 4
and 5, respectively), suggesting that the TNF-a-activated NF-kB
complex consisted of both p50 and p65 subunits. On the other
hand, an irrelevant anti-a-tubulin (lane 6) or oligonucleotide
specific to Oct1 (lane 8) or Sp1 (lane 9) had no effect. Thus,
MPTAG pretreatment significantly inhibited TNF-a-induced
activation of NF-kB in endothelial cells.
The inhibition of NF-kB activation by MPTAG was further
assessed by transfection of NF-kB-regulated luciferase reporter
construct in endothelial cells as described in ‘‘Methods’’. For this,
endothelial cells were transiently transfected with the luciferase
vector, preincubated with MPTAG and stimulated with TNF-a.
We observed that luciferase activity was significantly inhibited by
MPTAG (Figure 2D).
MPTAG inhibits TNF-a-induced NF-kB translocation in
endothelial cells
Since NF-kB activation requires the translocation of its p65
subunit to the nucleus, we measured the levels of p65 in the
cytoplasm and in the nucleus in MPTAG-pretreated cells. It was
Figure 1. The structures of MPG, a novel compound isolated
and purified from P. granatum leaves (A) and MPTAG, the most
active laboratory synthesized derivative of MPG (B).
doi:10.1371/journal.pone.0046528.g001
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observed that there were high levels of p65 in the cytoplasm of
unstimulated cells in absence and presence of MPTAG and the
levels were found to be very low in the nucleus (Figures 3A and
3B). Upon stimulation of cells with TNF-a, as expected, the levels
of p65 in the cytoplasm were decreased with a concomitant
increase in the nucleus (Figures 3A and 3B). MPTAG pretreated
TNF-a stimulated cells had higher cytoplasmic levels of p65 than
cells that were only TNF-a stimulated. There was a concomitant
decrease in the nuclear p65 levels (Figures 3A and 3B). These
results indicated that MPTAG prevented the translocation of NF-
kBp65 subunit into the nucleus of endothelial cells. This was
additionally confirmed by immunocytochemical analysis
(Figures 3C and 3D).
It is reported that TNF-a stimulation results in the phosphor-
ylation of p65 subunit of NF-kB in the cytoplasm, which is
required for its nuclear translocation and transcriptional activity
[29]. Therefore, we determined the effect of MPTAG on p65
phosphorylation in the cytoplasm. We observed that in cells
pretreated with MPTAG, TNF-a was unable to induce p65
phosphorylation (Figures 3E and 3F) indicating that MPTAG
inhibits p65 phosphorylation.
MPTAG prevents TNF-a-induced IkBa degradation by
inhibiting the IKK-b activation
To determine whether the inhibitory action of MPTAG on NF-
kB activation was due to inhibition of IkBa degradation and its
phosphorylation, we examined the IkBa and phosphorylated IkBa
levels in the cytoplasm. As expected, TNF-a induced the
degradation of IkBa within 10 mins, which was concomitant to
IkBa phosphorylation (data not shown). Interestingly, MPTAG
pretreatment inhibited TNF-a-induced phosphorylation
[Figures 4B and 4C panel (ii)] and degradation [Figures 4A and
4C panel (i)] of IkBa.
Since IKK-b is required for the phosphorylation of IkBa in
these cells, we investigated whether MPTAG affected IKK
activation. For this, we immunoprecipitated IKK-b from the
untreated and MPTAG-treated cells in absence and presence of
TNF-a induction and analyzed by western blot. Our results
showed that TNF-a induction activated IKK-b within 10 minutes
of its addition (Figure 4D) and MPTAG pretreatment appreciably
suppressed this activation in a dose-dependent manner (Figure 4E).
Interestingly, neither TNF-a nor MPTAG affected the protein
levels of IKK-b (Figures 4D and 4E, lower panels). To evaluate
whether MPTAG suppressed IKK activation directly by binding
physically to IKK-b, firstly IKK-b was immunoprecipitated from
Figure 2. MPTAG prevents the TNF-a-induced NF-kB transcription and activation in human endothelial cells. (A) The cells were
pretreated with or without 400 mM of MPG before induction with TNF-a (10 ng/ml) for 4 h. The total RNA of the cells was isolated and analysed by
RT-PCR. The intensity of transcripts was normalized with that of b-Actin levels expressed under similar conditions. (B) The cells were pretreated with
MPTAG at varying concentrations and then induced with TNF-a. The cytoplasmic (CE) and nuclear (NE) extracts were prepared from untreated and
MPTAG-treated TNF-a-stimulated cells (see ‘‘Methods’’). The nuclear extracts were analyzed for NF-kB activation by EMSA. (C) The nuclear extracts
from unstimulated or TNF-a-stimulated HUVECs were incubated with the indicated antibodies and analyzed for NF-kB activation by EMSA (see
‘‘Methods’’). (D) The cells were transiently transfected by electroporation with a NF-kB-containing luciferase reporter gene followed by treatment with
400 mM MPTAG and TNF-a stimulation. The supernatants after cell lysis were assayed for luciferase activity. The mean value for cells treated with no
MPTAG and no TNF-a was set to 1, and -fold differences were determined by comparing values against this set value. *p,0.005 vs. uninduced cells;
**p,0.01 vs. TNF-a-induced cells, statistical difference was set at p,0.05.
doi:10.1371/journal.pone.0046528.g002
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uninduced and TNF-a-induced cells followed by its incubation
with MPTAG and then performing the kinase assay. It was
observed that MPTAG did not affect the activity of IKK-b by
direct interaction (Figure 4F). Collectively these data suggest that
MPTAG blocked the TNF-a-induced activation of IKK-b but
neither bound IKK-b directly, nor changed the expression levels
of IKK-b.
MPTAG inhibits TNF-a-induced activation of Akt and its
association with IKK-b
Akt is implicated in the regulation of NF-kB activity by
activating IKK. Moreover, TNF-a has been shown to activate NF-
kB/Rel through the activation of Akt [10], [14]. This indicates the
possibility of suppression of TNF-a-induced Akt activation by
MPTAG. To examine the effect of MPTAG on activation of Akt
by TNF-a, we pretreated cells with MPTAG followed by
induction with TNF-a and performed western blot analysis to
determine the levels of Akt phosphorylation at both Thr308 and
Ser473 residues. The results showed that Akt was phosphorylated
in a time-dependent manner at both the residues in TNF-a-
stimulated human endothelial cells (Figure 5A). Interestingly,
MPTAG inhibited the phosphorylation of Akt at both the residues
without affecting the protein levels of Akt (Figures 5B and 5C).
Next we investigated whether MPTAG affected the association
of Akt with IKK-b. The results revealed that TNF-a induction
caused a time-dependent association of Akt with IKK-b
(Figure 5D), and MPTAG significantly prevented this association
in a dose-dependent (Figures 5E and 5F) and time-dependent
manner (Figure 5G) with no increase in the expression levels of
IKK-b in these cells.
As p38 and ERK are also known to be associated with NF-kB
activation [13], we tested whether these kinases, are also affected
by MPTAG pretreatment. Our results showed that both p38 and
ERK were activated in TNF-a stimulated cells but MPTAG
pretreatment had no effect on this activation (Figure 5H). These
results indicated that MPTAG specifically inhibited the association
of Akt with IKK-b in TNF-a stimulated human endothelial cells.
MPTAG inhibits Akt phosphorylation by a PI-3K
independent and PKA-dependent pathway
Akt is known to be regulated by upstream kinases PI-3K [14–
19], [30] and PKA [20–24]. To assess the specific roles of these
Figure 3. MPTAG prevents the TNF-a-induced NF-kB translocation in human endothelial cells. (A) The cells were pretreated with MPTAG
(400 mM) and induced with TNF-a. The cytoplasmic (CE) and nuclear (NE) extracts were prepared and processed for western blot analysis. (B) The
intensity of bands were densitometrically scanned and normalized with that of a-tubulin and Lamin B1 in CE and NE extracts, respectively. The values
presented are mean6 SEM. *p,0.005 vs. uninduced cells; **p,0.01 vs. TNF-a-induced cells, statistical significance was set at p,0.05. (C–D) The cells
were treated and induced as described in ‘A’ and subjected to immunocytochemical analysis using anti-NF-kBp65 and FITC-labeled anti-rabbit
antibodies. DAPI was used for staining the nucleus. The mean intensity levels of NF-kB conjugated to FITC, both in the cytoplasm and nucleus, were
quantitated and plotted as mean intensity 6 SEM. *,#p,0.05 vs. uninduced cells; **,##p,0.05 vs. TNF-a-induced cells, statistical difference was set
at p,0.05. The scale bars represent 50 mm (E–F) MPTAG inhibits TNF-a-induced p65 phosphorylation in endothelial cells. The cells were
treated and induced followed by western blot analysis as stated in ‘A’. The intensity of bands were densitometrically scanned and normalized with
that of a-actin levels. The values presented are mean 6 SEM. *p,0.05 vs. uninduced cells; **p,0.02 vs. TNF-a-induced cells, statistical difference was
set at p,0.05.
doi:10.1371/journal.pone.0046528.g003
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kinases, expressed in human endothelial cells, on Akt phosphor-
ylation, we pretreated these cells with specific inhibitors of PI-3K
(wortmannin) and PKA (H-89) before TNF-a induction. We
observed that wortmannin inhibited Akt phosphorylation whereas
H-89 enhanced it (Figure 6A). Thus, TNF-a-induced Akt
phosphorylation was positively regulated by PI-3K and negatively
by PKA in HUVECs.
To examine whether MPTAG inhibits Akt phosphorylation by
blocking the activity of PI-3K in these cells, the effect of MPTAG
with or without wortmannin treatment was assessed. It was
observed that MPTAG treatment had no effect on TNF-a-
induced PI-3K activity (Figure 6B). To confirm the functional
consequence of modulation of Akt phosphorylation, we assessed
the NF-kB activation by EMSA. Expectedly, the results showed
that wortmannin treatment inhibited and H-89 treatment
enhanced the NF-kB activation in TNF-a-stimulated cells
(Figure 6C).
Further experiments were then performed to determine the
mechanism for the inhibitory effect of MPTAG on TNF-a-
induced Akt phosphorylation. The effects of MPTAG on TNF-a-
induced Akt phosphorylation was measured in absence and
presence of wortmannin or H-89. The results revealed that
MPTAG dose-dependently inhibited Akt phosphorylation, inde-
pendently of wortmannin [Figure 6D panels (i,ii)]. Moreover, NF-
kB activation, measured by EMSA, was inhibited similarly in
presence or absence of wortmannin (Figure 6E), suggesting that
the mechanism of action of MPTAG was not through PI-3K
inhibition.
In contrast, H-89 added prior to MPTAG showed an
interaction where the inhibitory effect of MPTAG was completely
abolished by H-89, thereby restoring TNF-a-induced Akt
phosphorylation [Figure 6D panels (i,iii)]. Further EMSA experi-
ments showed that MPTAG alone significantly inhibited NF-kB
activation; H-89 treatment alone enhanced it; when H-89
treatment preceded MPTAG, the activation remained increased;
and when MPTAG treatment preceded H-89, the activation was
inhibited (Figure 6F).
This strongly suggested that MPTAG and H-89 have opposite
actions on PKA-Akt axis. The data best fitted a model where
activation of PKA by MPTAG inhibits Akt phosphorylation,
thereby inhibiting NF-kB activation, in TNF-a-induced human
endothelial cells.
MPTAG restores PKA activity in TNF-a-stimulated
endothelial cells
To validate the model, we checked the levels of PKA kinase
activity in human endothelial cells. The results, shown in
Figure 7A, revealed the presence of appreciable PKA activity in
unstimulated HUVECs. Since PKA activation is mostly regulated
through the cAMP-dependent pathway involving adenylate
cyclase activation, we tested whether MPTAG has any effect on
the activity of this enzyme. We observed that PKA activity was
Figure 4. MPTAG prevents TNF-a-induced IkBa degradation by inhibiting the activation of IKK-b. (A–B) The cells were treated with
MPTAG (400 mM) followed by induction with TNFa for 30 mins and total cell extracts were processed for western blot analysis using antibodies
against IkBa, phosphoIkBa and a-tubulin. (C) The intensity of bands were densitometrically scanned and normalized with that of a-tubulin in panels
(i) and (ii). The values presented are mean 6 SEM. *p,0.005 vs. uninduced cells; **p,0.01 vs. TNF-a-induced cells, statistical significance was set at
p,0.05. (D) The cells were treated with MG-132 (a proteosome inhibitor; 50 mg/ml) for 30 mins and then exposed to TNF-a (10 ng/ml) for the
indicated times. Total cell extracts were prepared and immunoprecipitated with anti-IKK-b antibody followed by kinase assay using GST-IkBa as a
substrate. The extracts were also subjected to western blot analysis using anti-IKK-b antibody. (E) The cells were treated with MPTAG and MG-132 and
then induced with TNF-a for 30 mins followed by kinase assay and western blot analysis as stated above. (F) The total cell extracts were prepared
from cells in absence and presence of TNF-a induction (10 ng/ml) and were immunoprecipitated with anti-IKK-b antibody. The kinase assay was
performed in the absence or presence of the indicated concentrations of MPTAG. The extracts were also subjected to western blot analysis using anti-
IKK-b antibody.
doi:10.1371/journal.pone.0046528.g004
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moderately suppressed with adenylate cyclase inhibitor SQ 22536
treatment alone but remained increased when MPTAG and SQ
22536 were added together. PKA activity was also found to be
significantly repressed upon TNF-a stimulation to these cells.
MPTAG added alone or together with SQ 22536 restored PKA
activity to levels similar to that of unstimulated cells (Figure 7A).
H-89 treatment inhibited PKA activity, even in presence of
MPTAG. Thus, restoration of repressed PKA activity by MPTAG
is independent of the classical cAMP-dependent regulatory
pathway but remains susceptible to catalytic subunit inhibitors
like H-89.
Discussion
Here, we demonstrate for the first time that a novel compound,
MPTAG, inhibits NF-kB activation by blocking the phosphory-
lation of Akt, through a PI-3K independent mechanism, in TNF-
a-stimulated HUVECs. As NF-kB is a key regulator of various
inflammatory and cellular immune responses and its aberrant
expression leads to many pathological conditions, identifying small
molecules for regulating NF-kB is an intensive area of research
[31]. Over the years, numerous molecules have been identified
that blocked the activation of NF-kB by intervening with the
signaling through the canonical NF-kB pathway, however, in the
present study we provide the first evidence that NF-kB could also
be regulated through the PKA/Akt axis in TNF-a-stimulated
HUVECs.
The present study identified a novel small molecule MPTAG, a
derivative of plant-derived molecule MPG that blocked TNF-a-
induced NF-kB activation in HUVECs, through inhibition of Akt
activation and subsequent inhibition of Akt-IKK association. An
outline of our findings is illustrated in Figures 7B and 7C. Our
results revealed that MPTAG inhibited the NF-kB activation
through blocking the phosphorylation and degradation of IkBa
and nuclear translocation of NF-kBp65 subunit in HUVECs.
Since direct incubation of MPTAG with the immunoprecipitated
IKK-b showed no effect on its activity, it is likely that MPTAG
inhibits NF-kB activation through the suppression of TNF-a-
Figure 5. MPTAG inhibits the TNF-a-induced Akt activation and its association with IKK-b. (A) The cells were induced with TNF-a (10 ng/
ml) for the indicated times. The total cell extracts were prepared and subjected to western blot analysis using anti-phosphoAkt, for both Ser473 and
Thr308 residues, and anti-Akt antibodies. (B) The cells were treated with MPTAG (400 mM) and induced with TNF-a for 30 mins followed by western
blot analysis as stated above. (C) The intensity of bands were densitometrically scanned and normalized with total Akt levels. The values presented
are mean6 SEM. *p,0.05 vs. uninduced cells; **p,0.05 vs. TNF-a-induced cells, statistical significance was set at p,0.05. (D) The cells were induced
with TNF-a (10 ng/ml) for the indicated times. The total cell extracts were prepared and immunoprecipitated with anti-IKK-b antibody followed by
western blot analysis with anti-Akt and anti-IKK-b antibodies. (E) The cells were pretreated with MPTAG at varying concentrations and induced with
TNF-a for 30 mins. The total cell extracts were prepared and processed as stated above and analyzed for western blot as stated above. (F) The
intensity of bands were densitometrically scanned and normalized with IKK-b levels. (G) The cells were pretreated with 400 mM MPTAG and then
stimulated with 10 ng/ml TNF-a for the indicated times. The total cell extracts were prepared, immunoprecipitated with anti-IKK-b antibody and
analyzed by western blot using anti-Akt and anti-IKK-b antibodies. (H) Effect of MPTAG on TNF-a-induced p38 MAPK and ERK1/2 activation.
The cells were treated with MPTAG and induced with TNF-a as stated above. The total cell extracts were prepared and analyzed by western blot using
anti-phosphospecific p38 MAPK and ERK1/2 antibodies. The same membrane was reblotted with anti-p38 MAPK, ERK 1/2 and b-actin antibodies. The
values presented are mean 6 SEM. *p,0.05 vs. uninduced cells; **p,0.05 vs. TNF-a-induced cells, statistical significance was set at p,0.05.
doi:10.1371/journal.pone.0046528.g005
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induced IKK-b activation. Akt, also activated by TNF-a, has been
shown to associate with and subsequently activate IKK as shown
previously in cells other than HUVECs [10], [32]. In this study,
we showed that TNF-a stimulation resulted in increased Akt
activation and time-dependent association of Akt to IKK-b. In this
context, we demonstrated that MPTAG pretreatment inhibited
both the TNF-a-induced Akt activation as well as Akt-IKK-b
association. Collectively, these results indicated that MPTAG
blocked IKK-b activation by suppressing Akt activation in these
cells. Most importantly, the lack of effect of MPTAG on TNF-a-
induced ERK and p38 MAPK activation suggested specificity of
its action on Akt in these cells. Consistent with the previous
findings that TNF-a-induced Akt activation augments NF-kBp65
transactivation [29], [33], we showed that p65 phosphorylation
increased in a time-dependent manner upon TNF-a stimulation in
HUVECs. Interestingly, MPTAG was found to inhibit the TNF-a-
Figure 6. MPTAG blocks Akt activation and NF-kB activation in a PI-3K independent and PKA-dependent manner in TNF-a-
stimulated HUVECs. (A) The cells were either preincubated with wortmannin (100 mM) or H-89 (20 mM) for 30 mins and then induced with TNF-a
(10 ng/ml) for additional 30 mins. The total cell extracts were subjected to western blot analysis using anti-phospho-Akt (Thr308) and anti-Akt
antibodies. (A; lower panel) The intensity of bands were densitometrically scanned and normalized with Akt levels. The values presented are mean 6
SEM. *p,0.02 vs. uninduced cells; **p,0.05 vs. TNFa-induced cells, statistical difference was set at p,0.05. (B) The cells were pretreated with
wortmannin in absence and presence of MPTAG before induction with TNF-a. The total cell extracts were subjected to PI3K assay (see ‘‘Methods’’).
The mean value (in pmol) for cells treated with neither MPTAG nor TNF-a (control) was set to 1, and -fold changes were determined by comparing
values against this set value. The values presented are mean 6 SEM. *p,0.002 vs. uninduced cells; **p,0.005 vs. TNF-a-induced cells, statistical
significance was set at p,0.05. (C) The cells were treated and induced as described in (A). The nuclear extracts were assessed for NF-kB activation by
EMSA. Effect of MPTAG on Akt phosphorylation in absence and presence of wortmannin and H-89 in TNF-a-stimulated HUVECs. (D;
panels (i–iii)). For this, the cells were incubated without or with either wortmannin or H-89 before treatment with different concentrations of MPTAG
followed by induction with TNF-a. The total cell extracts were subjected to western blot analysis using anti-phospho-Akt (Thr308) and anti-Akt
antibodies. Effect of MPTAG on NF-kB activation in absence and presence of wortmannin and H-89 in TNFa-stimulated HUVECs. (E–F)
The cells were treated and induced as stated in (D). The nuclear extracts were prepared and assessed for NF-kB activation by EMSA.
doi:10.1371/journal.pone.0046528.g006
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induced p65 phosphorylation in these cells. It is important to note
that as TNF-a is the early proinflammatory cytokine released from
LPS- or phorbol ester-stimulated macrophages and neutrophils
[34], [35], MPTAG could also be effective for inhibiting NF-kB
activation in inflammatory conditions initiated by these agents.
Further investigations were aimed at elucidating the mechanism
through which MPTAG inhibited TNF-a-induced Akt activation
in HUVECs. In this context, our results revealed that TNF-a
stimulation increased the PI-3K activity in these cells. However,
pretreatment of these cells with wortmannin abolished this
activation whereas, MPTAG pretreatment had no effect on this
activation indicating MPTAG acts independent of conventional
PI-3K inhibition in HUVECs. There are numerous reports that
showed either positive [20], [21] or negative [22–24], [36]
regulation of Akt by Protein kinase A (PKA) in various cell types
excluding HUVECs. Our study demonstrated that TNF-a
stimulation resulted in repression of PKA activity and increased
activation of PI-3K and NF-kB pathways in HUVECs. This is in
agreement with a report that showed that TNF-a could
downregulate PKA activity in podocytes [37]. Interestingly,
MPTAG significantly restored the repressed PKA activity in
TNF-a-stimulated HUVECs independent of adenylyl cyclase
activation. It is probable that restoration of the otherwise repressed
PKA activity, by MPTAG, leads to the PI-3K independent
inhibition of Akt. We speculate that high constitutive baseline
activity of PKA in these cells precludes further activation by
MPTAG except when the activity has been repressed by TNF-a,
permitting derepression. Interestingly, we observed that MPTAG
had no significant inhibitory effect on the basal NF-kB activation,
but PKA can still signal at a basal level without TNF-a
stimulation.
MPTAG showed improved properties in terms of aqueous
solubility, cellular tolerability and inhibitory activity (Tables S1,
S2, S3). MPTAG, used at 400 mM, showed complete inhibition of
NF-kB activation without affecting the morphology and viability
in HUVECs. Here, we would like to mention that this is not as
high as the concentrations at which non-steroidal anti-inflamma-
tory molecules like sodium salicylate, aspirin, N-acetyl cysteine,
diclofenac inhibit NF-kB [38–41] and this study did not intend to
propose MPTAG as a unique specific NF-kB inhibitor. Impor-
tantly, unlike small molecules that directly inhibit IKK-b,
MPTAG only suppressed its activation. This action of MPTAG
would contribute towards overcoming the undesirable effects
caused by specific IKK-b inhibitors in animal models [42]. We
speculate that MPTAG or its improved analogues along with other
small molecule IKK inhibitors could provide robust inhibition of
NF-kB in severe inflammatory disease conditions where both
PKA/Akt axis and IKK pathways are modulated.
Materials and Methods
Ethics statement
Human umbilical cords were obtained from St. Stephens
Hospital, Delhi, India. A formal ethical clearance certificate, to
collect the human cord sample, was obtained from the hospital
ethics committee.
Reagents
D-glucose, red phosphorus, acetic anhydride, HClO4, maltol,
silver carbonate, dichloromethane, ethyl acetate, petroleum ether
were purchased from Qualigens Fine Chemicals (India). M199
powdered medium, L-glutamine, endothelial cell growth factor
(ECGF), trypsin, penicillin, streptomycin, amphotericin B, di-
methyl sulfoxide (DMSO), MTT, wortmannin, H-89, SQ 22536,
GST-IkBa(1–54) substrate, goat anti-mouse IgG conjugated to
HRP, mouse IgG conjugated to FITC, goat anti-rabbit IgG
conjugated to HRP and Protein G immunoprecipitation kit were
purchased from Sigma Chemical Co. (St. Louis, MO). Fetal calf
serum (FCS), EZ-RNA isolation kit and EZ-first strand cDNA
synthesis kit were purchased from Biological Industries (Kibbutz
Beit Haemek, Israel). Antibodies against human ICAM-1, VCAM-
1, E-selectin and recombinant human tumor necrosis factor-a
(TNF-a) were purchased from BD Pharmingen (San Diego, CA).
Primer sets for RT-PCR of human ICAM-1, VCAM-1, E-selectin
and b-Actin genes were custom synthesized by Genset Corpora-
tion (Tokyo, Japan). NF-kB and Oct-1 oligonucleotides for
electrophoretic mobility shift assay (EMSA), Profluor PKA activity
and luciferase assay kits were purchased from Promega Inc.
(Madison, USA) and Class III PI3-kinase kit was obtained from
Echelon (USA). Antibodies against NF-kBp65 (C-20), phospho
NF-kBp65, IkBa, phosphoIkBa, IKK-b, Akt, phosphoAkt(-
Ser473), phosphoAkt(Thr308), PKAa(W-18), p85a(N-18), a-tubu-
Figure 7. MPTAG restores PKA activity in TNFa-stimulated HUVECs. (A) The cells were treated with media (control), MPTAG, SQ 22536, H-89
or their indicated combinations in absence and presence of TNF-a stimulation. PKA activity was assessed in the cell lysates. Results are expressed as
mean 6 sem of three independent experiments. *p,0.05 vs. control. Proposed model of MPTAG action in TNF-a-stimulated HUVECs. (B) In
TNF-a-stimulated HUVECs (without MPTAG treatment), PI-3K-regulated Akt is activated (indicated by solid line arrow) resulting in NF-kB activation.
On the other hand, PKA activity remained repressed (indicated by broken line arrow) under these conditions. (C) MPTAG pretreatment to TNF-a-
stimulated HUVECs restored the repressed activity of PKA. Thus, derepression of PKA activity resulted in inhibition of Akt and overall inhibition of NF-
kB in these cells.
doi:10.1371/journal.pone.0046528.g007
NF-kB Regulation through PKA/Akt in HUVECs
PLOS ONE | www.plosone.org 8 October 2012 | Volume 7 | Issue 10 | e46528
lin and Lamin B1 were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA).
Synthesis of MPTAG
Detailed experimental protocol afforded the synthesis of 2-
methyl-pyran-4-one-3-O-b-D-29,39,49,69-tetra-O-acetyl glucopyr-
anoside (MPTAG) (4, Figure S1). In the synthetic scheme, b-D-
glucose was treated with HClO4, red phosphorous, acetic
anhydride followed by water afforded 1-bromo-2,3,4,5-tetra-O-
acetyl-b,a-D-glucopyranoside (3) [43] which with maltol (2) in
presence of silver carbonate as catalyst produced MPTAG (4) [44].
To a solution of 3-hydroxy-2-methyl-4-pyrone (2; 0.12 g,
0.95 mmol) in dry dichloromethane (50 ml) in 4 A˚ molecular
sieves (1.0 g) was added acetobromoglucose (3; 0.41 g, 1.68 mmol)
and silver carbonate (1.4 g, 5 mmol) in succession. The mixture
was stirred at room temperature for four days. The suspension was
then filtered through small length celite and evaporated to dryness
under reduced pressure. The residue was chromatographed over
silica gel using petroleum ether and increasing proportion of ethyl
acetate. Petroleum ether: ethyl acetate eluent (7:3) afforded pure
MPTAG (4, Figure S1) as colorless sticky solid (0.278 g, 61%).
2-methyl-pyran-4-one-3-O-b-D-29,39,49,69-tetra-O-
acetylglucopyranoside [MPTAG (4)]
IR: nmax (KBr, cm
21): 2924, 2847, 1762, 1372, 1212; 1H-NMR
(300 MHz, DMSO-d6) : d 1.91 (s, 3H), 1.97 (s, 3H), 1.98 (s, 3H),
2.04 (s, 3H), 2.26(s, 3H), 3.96–4.15 (m, 3H), 4.91–4.99 (m, 2H),
5.23 (d, J = 7.8 Hz, 1H), 5.32–5.38 (m, 1H), 6.37 (d, J = 5.6 Hz,
1H), 8.07 (d, J = 5.6 Hz, 1H); 13C-NMR (75 MHz, DMSO-d6): d
15.77, 21.12, 21.24 (2C), 21.37, 62.25, 68.96, 71.48, 71.94, 72.48,
100.28, 117.42, 141.88, 156.25, 161.93, 170.22 (2C), 170.39,
170.81, 173.64 ESI MS m/z: 478.92 [M+Na]+; Anal. Calcd for
C20H24O12: C, 52.63; H, 5.30. Found: C, 52.34; H, 5.19.
Human umbilical vein endothelial cells (HUVECs) culture
Primary endothelial cells were isolated from human umbilical
cord as described previously [28]. The cells were grown in M199
medium supplemented with 15% heat inactivated fetal calf serum,
2 mM L-glutamine, 100 units/ml penicillin, 100 mg/ml strepto-
mycin, 0.25 mg/ml amphotericin B, and endothelial cell growth
factor (ECGF; 50 mg/ml).
Preparation of stock solutions of MPG and its derivatives
Stock solutions of MPG and its derivatives (Tables S1, S2, S3)
were prepared either in dimethylsulphoxide (DMSO) or cell
culture medium. MPG and its derivatives were diluted to working
concentrations in cell culture medium. The highest concentration
of DMSO in control wells was 0.25% which did not alter the
morphology, viability of the cells and had no effect on ICAM-1
assay (data not shown).
Cytotoxicity assay
The cytotoxicity of MPG and its derivatives was analyzed by
colorimetric assay using MTT (Thiazolyl blue tetrazolium
bromide) reagent as described previously [28]. All experiments
were performed at least 3 times in triplicate wells. From this assay,
the percentage viability (% viability) of the cells at various
concentrations of each compound was determined by normaliza-
tion to control wells that contained cells incubated in vehicle
(0.25% DMSO or cell culture medium) and which were
considered 100% viable. The highest concentration at which the
viability of the cells was .95% was denoted as the maximum
tolerable concentration for that compound.
Cell-ELISA for measurement of ICAM-1, VCAM-1 and E-
selectin expression
The endothelial cells were incubated with or without MPG and
its derivatives at various concentrations for 2 h followed by
treatment with TNF-a (10 ng/ml) for 16 h for ICAM-1 and
VCAM-1 expression and 4 h for E-selectin expression. A Cell-
ELISA was used to assess the expression of ICAM-1, VCAM-1
and E-selectin on the surface of endothelial cells as described
previously [28].
Neutrophil adhesion assay
Neutrophils were isolated from peripheral blood of healthy
individuals and neutrophil adhesion assay was performed under
static conditions as described previously [28], [45].
Preparation of cytoplasmic and nuclear extracts
The endothelial cells were subjected to the indicated treatments
followed by induction with TNF-a for indicated time points or
30 mins. The cells were then washed with PBS and dislodged
using a cell scraper. The cytoplasmic and nuclear extracts were
prepared as described previously [28], [46].
Total RNA isolation and Reverse Transcription-
Polymerase Chain Reaction (RT-PCR)
In order to examine whether MPTAG reduced the mRNA
transcript levels of cell adhesion molecules genes, the endothelial
cells were pretreated with 400 mM MPTAG for 2 h before
induction with TNF-a for 4 h followed by RT-PCR. RNA was
isolated from MPTAG-treated cells according to a modified
guanidinium thiocyanate procedure. The expression of the
transcripts for ICAM-1, VCAM-1 and E-selectin was evaluated
by RT-PCR [45]. b-Actin levels expressed under similar
conditions were used as a loading control.
Nuclear transcription factor-kB (NF-kB) activation assay
NF-kB activation in the nuclear extracts of human endothelial
cells was assessed by electrophoretic mobility shift assay (EMSA) as
described previously [45], [46]. For supershift experiment, nuclear
extracts prepared from unstimulated and TNF-a-stimulated cells
were incubated with antibodies against the p50 or p65 subunit of
NF-kB or -a-tubulin for 15 mins at 37uC before the complex was
analyzed by EMSA. Addition of equal amount of radioactive-
labelled probe to all the samples was indicated by the similar
intensity of the unincorporated probe observed towards the end of
the gel.
NF-kB reporter gene assay
NF-kB dependent reporter gene transcription was measured as
per the instructions of the luciferase assay kit (Promega, USA).
Briefly, human endothelial cells (26106 cells/well) were plated in
96-well plates. HUVECs were transiently transfected by electro-
poration with a NF-kB-containing luciferase reporter gene plasmid
for 24 h. After transfection, cells were washed and treated with
400 mM MPTAG for 24 h. For the TNF-a stimulation, cells were
treated with 10 ng/ml of TNF-a for another 24 h. Supernatants
after cell lysis were assayed for luciferase activity. The mean value
for cells treated with no MPTAG and no TNF-a was set to 1, and -
fold differences were determined by comparing values against this
set value. Cells were co-transfected with a control vector
expressing b-galactosidase under SV40 promoter to normalize
transfection efficiency.
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Immunochemical staining of HUVECs
To study the effect of MPTAG on nuclear translocation of NF-
kBp65 subunit in presence of TNF-a-stimulation, the HUVECs
were seeded on gelatinized glass bottom 6-well plate at a cell
density of 0.36106 cells/ml. Following day, media was changed
and MPTAG was added to the cells for 2 h. After the end of drug
pretreatment, cells were induced with TNF-a for 45 mins. The cell
monolayers were washed with PBS (phosphate buffered saline
containing 1 mM CaCl2 and 1 mM MgCl2) and were fixed in a
solution, containing 4% paraformaldehyde in 120 mM sodium
phosphate buffer pH 7.2–7.4, for 20 mins at room temperature.
The cells were then permeabilized using a high salt buffer,
containing 0.45 M NaCl and 20 mM sodium phosphate buffer
pH 7.2–7.4, 0.3% Triton X-100 and 0.2% gelatin, for 1 h at room
temperature. Following this, the cells were incubated with anti-
NF-kBp65 antibody for 2 h at room temperature. The excess
antibody was washed five times with high salt buffer to ensure
removal of unbound antibody. This was followed by incubation
with anti-rabbit FITC-labeled secondary antibody for 1 h at room
temperature. The cells were washed five times with high salt buffer
and the final wash with PBS containing 1 mM CaCl2 and 1 mM
MgCl2. The cells were mounted using a mounting medium
containing DAPI and anti-fade agent. The cells were observed
under a Nikon fluorescent microscope. The fluorescent signals
were then quantitated by selecting the nuclear and cytoplasmic
regions in different fields using the NTS imaging software.
Immunoprecipitation protocol
In brief, confluent HUVECs were incubated with or without
MPTAG and were stimulated with TNF-a (10 ng/ml) for
15 mins. The cells were washed and lysed in Lysis buffer
containing 50 mM HEPES, pH 7.6, 10% glycerol, 1 mM sodium
orthovanadate, 100 mM NaCl, 1% NP-40, 1 mM EDTA and
protease inhibitor cocktail and allowed to swell on ice for 45 mins.
Following centrifugation at 13,000 rpm for 45 mins, the superna-
tants were collected as ‘‘total cell extracts’’ and stored at 270uC.
Immunoprecipitation was performed as per the instructions of
Protein G immunoprecipitation kit (Sigma Aldrich, USA).
Endogenous IKK complexes were immunoprecipitated in the
following reaction mixtures: 100–300 mg of total cell extracts were
incubated with 2–4 mg anti-IKK-b or PKAa antibody in 100 ml
16 IP buffer. After incubation for 16 h at 4uC with constant
shaking, 50 ml of activated protein G beads were added and the
mixture was incubated under rotation for an additional 3 h at 4uC.
IKK-b kinase assay
Kinase assay was performed as previously described [32].
Immunoprecipitates from 100 mg of total cell extracts were used
for kinase assays. The reaction mixture consisted of kinase buffer
(20 mM Tris Cl, pH 7.6, 1 mM EDTA, 1 mM sodium orthova-
nadate, 20 mM MgCl2, 2 mM DTT), 2 mg GST-IkBa(1–54),
5 mM ATP and 1 mCi [c 32P] ATP in a volume of 30 ml. Kinase
reactions were performed at 37uC for 30 mins and then subjected
to SDS-PAGE and autoradiography.
Western blot analysis
Nuclear and cytoplasmic extracts were fractionated on SDS-
PAGE with equal amount of proteins per well and transferred onto
PVDF membranes and those membranes were incubated with
appropriate primary antibodies and treated with HRP conjugated
secondary antibodies followed by detection with DAB-H2O2
system. b-tubulin, a-actin and Lamin B1 were used as loading
controls. Antibodies against NF-kBp65, phosphoNF-kBp65, IkBa,
phosphoIkBa, IKK-b, Akt, phosphoAkt (Ser473) and phosphoAkt
(Thr308) were used.
Protein kinase A (PKA) activity assay
PKA was immunoprecipitated from the total cell lysates of
unstimulated and TNF-a-stimulated endothelial cells in presence
and absence of treatment with agents indicated in Figure 7 using
anti-PKAa (W-18) antibody. The immunoprecipates were sub-
jected to kinase activity assay using a Bisamide Rhodamine 110
peptide substrate as per the instructions of the Profluor PKA assay
kit (Promega, USA).
Phosphoinositide-3-kinase (PI-3K) activity assay
The catalytic domain of PI-3K was immunoprecipitated from
the stimulated and unstimulated endothelial in presence and
absence of various compound treatment using an anti-p85a (N-18)
antibody. The immunoprecipated proteins were subjected to
kinase activity assay using a PI substrate, diC8 followed by
detection of the PI(3)P as per the instructions of the Class III PI-
3kinase kit (Echelon, USA).
Statistical analysis
Data are expressed as means 6 standard error of the mean
(s.e.m). For comparisons between two selected groups, we used
unpaired student’s ‘t’ test. For comparisons between multiple
groups, ANOVA with Bonferroni’s correction was used. A value of
p,0.05 was considered statistically significant. Analyses were done
using JMP (version 4.0) and GraphPad Prism (version 5.0)
softwares.
Supporting Information
Figure S1 Scheme of synthesis of 2-methyl-pyran-4-one-
3-O-b-D-29,39,49,69-tetra-O-acetyl glucopyranoside
(MPTAG). In the synthetic scheme, b-D-glucose was treated
with HClO4, red phosphorous, acetic anhydride followed by the
water afforded 1-bromo-2,3,4,5-tetra-O-acetyl-b,a-D-glucopyra-
noside (3) which with maltol (2) in presence of silver carbonate
(Ag2CO3) and CH2Cl2 as catalyst gave the MPTAG (4).
(TIF)
Table S1 Structures of derivatives of 2-methyl-pyran-4-
one-3-O-b-D-glucopyranoside (MPG). The derivatives of
parent compound MPG were synthesized in the laboratory and
their structures were determined by spectroscopic methods.
(TIF)
Table S2 Cytotoxicity profiles and ICAM-1 inhibitory
activities of the parent compound (MPG) and its
derivatives. The data are expressed as mean 6 s.e.m. The
results are representative of three independent experiments.
(TIF)
Table S3 The inhibitory profile of MPTAG vs. MPG on
human endothelial cells. The data are expressed as mean 6
s.e.m. The results are representative of three independent
experiments.
(TIF)
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